The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding ...

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in ...

Please provide your email address to receive an email when new articles are posted on . Previous studies investigated whether surgery may extend survival among patients with malignant pleural ...

Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed. The addition of surgery ...

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer ...

Chemical pleurodesis. The surgeon puts a chemical, usually talc, into the pleural space (the space between your lungs and your chest wall.)‌ Mechanical pleurodesis. The surgeon abrades (brushes) the ...

Age alone should not be an exclusion criterion for extended pleurectomy decortication among elderly patients with malignant pleural mesothelioma, according to a review of prospectively collected data ...

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of ...

Researchers have developed a new method for filling and sealing pleural cavities. The process consists of injecting polyurethane foams into the lungs with a self-expanding and self-modelling capacity ...

The excessive buildup of fluid in the space between your lungs and chest cavity, known as water fluid is also called Pleural effusion. The condition in which both the lungs get affected is called ...

The median survival of patients undergoing trimodality therapy is 1–2 years, but some patients (19%) can live for 3–14 years. To improve outcomes and survival, the focus of clinical research over the ...